Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy – £10m in milestone payments received from GlaxoSmithKline
Leiden, the Netherlands, October 23, 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.
Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055, designed for the skipping of exons 52 and 55 of the dystrophin gene. PRO052 and PRO055 are currently in pre-clinical development and will be moved to clinical trials as soon as possible.
College Hill Life Sciences – Anastasios Koutsos / Henry Stanley